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Abstract
Health technology assessment (HTA) systems across countries vary in the way they are set up, according to their role and 
based on how funding decisions are reached. Our objective was to study the characteristics of these systems and their likely 
impact on the funding of technologies undergoing HTA. Based on a literature review, we created a conceptual framework 
that captures key operating features of HTA systems. We used this framework to map current HTA activities across 32 
countries in the European Union, the UK, Canada and Australia. Evidence was collected through a systematic search of 
competent authority websites and grey literature sources. Primary data collection through expert consultation validated our 
findings and further complemented the analysis. Sixty-three HTA bodies were identified. Most have a national scope (76%), 
are independent (73%), have an advisory role (52%), evaluate pharmaceuticals predominantly or exclusively (76%), assess 
health technologies based on their clinical and cost-effectiveness (73%) and involve various stakeholders as members of the 
HTA committee (94%) and/or through external consultation (76%). The majority of HTA outcomes are  not legally binding 
(81%). Although all study countries implement HTA, the way it fits into decision-making, negotiation processes, and cover-
age and funding decisions differs significantly across countries. HTA is a dynamic and transformative process and there is 
a need for transparency to investigate whether evidence-based information influences coverage decisions.
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1  Background
Health technology assessment (HTA) is “the systematic 
evaluation of properties, effects and/or impacts of health 
technology” [1]. It aims to improve both quality and value 
for money [2, 3] and facilitate coverage decisions based on 
evidence-based information and other socioeconomic factors 
beyond the clinical and cost-effectiveness of a technology. 
HTA comprises multiple operational features and practices, 
the application of which may differ substantially by setting, 
resulting in different use and application [4, 5]. The context 
and structure of HTA systems reflect health system priori-
ties and underpin a country’s history, culture, values and 
preferences. Therefore, HTA is a concept with many facets 
and may differ in its focus and method, its governance and 
role, scope and remit, the assessment method employed and 
its impact on coverage decisions [6–12]. Taking into consid-
eration these variations, it is important to study the different 
HTA parameters that can influence the way HTA systems are 
set up, operate and are integrated within national policies. 
These variations make HTA processes unique, resulting in 
different levels of use, implementation and impact on the 
decision-making process and final coverage decision [13]. 
Whilst some countries directly translate HTA recommenda-
tions into coverage decisions, this may not be the case in 
others where HTA only provides an assessment to be used 
by healthcare systems when deciding whether health tech-
nologies should be included in the reimbursement list or not.
Our main objectives are threefold: first, to understand the 
multiplicity of approaches employed by different HTA bod-
ies across a wide range of countries; second, to study the role 
of HTA within the healthcare system and the extent to which 
it is integrated into or is independent of the healthcare sys-
tem and what this implies for HTA recommendations; and, 
third, to identify the link between HTA recommendations 
and funding decisions.
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Key Points for Decision Makers 
Health technology assessment (HTA) is an evidence-
based tool used to inform funding and coverage deci-
sions by healthcare systems at national and/or regional 
level. Key features of HTA and their operationalisation 
within settings can have an impact on whether, and to 
what extent, HTA recommendations influence funding 
and coverage decisions.
While there are well-developed HTA processes for the 
assessment of pharmaceuticals, there is an urgent need 
for the development of established HTA processes for 
medical devices and other technologies, such as public 
health interventions.
Even though HTA is now present across many settings, 
a lack of transparency in reimbursement and negotiation 
processes results in a limited understanding of whether 
or not HTA recommendations are considered in coverage 
decisions in practice. Because of this, there is a need to 
make these processes more transparent.
functions [6, 14–16]. In order to understand better why reim-
bursement decisions differ amongst jurisdictions using HTA 
and to systematically showcase similarities and differences 
among HTA systems, we propose a conceptual framework 
that captures the salient features of HTA systems (Fig. 1). 
We reviewed and analysed existing frameworks focusing on 
how HTA is organised and how it operates within health-
care systems [17–26]. To identify relevant literature, we con-
ducted a search through Medline and Scopus and a targeted 
search on the websites of the European network for Health 
Technology Assessment (EUnetHTA) and the European 
Commission. We searched Medline and Scopus using the 
following keywords: ‘health technology assessment’, ‘value 
assessment’, ‘comparative assessment’ and ‘framework’. We 
limited the search to English language and set up the study 
period for inclusion from 2005 to 2017. The start date of the 
search timeframe was selected based on the period when 
independent HTA bodies with refined responsibilities started 
to be established [17–19]. We screened studies through titles 
and abstracts and selected studies for inclusion only when 
the authors had designed a conceptual or analytical frame-
work looking at HTA systems, their operation within coun-
tries and their potential role in reimbursement. We excluded 
studies using existing frameworks created by other authors 
and studies focusing only on the HTA process and the evalu-
ation of the clinical and economic evidence, as they were 
outside the scope for our study. For the targeted search, we 
navigated the websites of EUnetHTA and the European 
Commission to identify recent studies focusing on Euro-
pean HTA systems, as these studies often draw comparisons 
across the systems of EU member states. We navigated the 
websites by using the search tool of both websites and the 
same keywords used in the literature search.
Based on our findings, existing frameworks [17–26] (a) 
focus on the HTA process itself in combination with few 
structural features such as the role of HTA, topic selec-
tion, or stakeholder involvement; (b) examine HTA as a 
reimbursement policy that determines technologies’ avail-
ability within markets, specifically focusing on manufac-
turers’ perspectives; (c) explore decision-making criteria 
at HTA level; or (d) analyse key components such as level 
of transparency and scientific rigour, which could influ-
ence HTA recommendations. Our framework, in contrast 
to existing ones, provides a holistic overview capturing the 
main operational components of HTA together with salient 
features of HTA systems and their interactions, to help us 
understand how HTA processes differ across settings and 
why, how HTA systems function, and whether HTA rec-
ommendations are likely to be directly linked to coverage 
decisions or not.
In this paper we develop and extend a conceptual frame-
work capturing the main operational pillars of HTA. We 
consider HTA within the broader healthcare system with 
a view to understanding the links between assessment of 
new technologies, their appraisal and the implications for 
coverage and funding. Using this framework, we map HTA 
activities and analyse HTA systems from an international 
and comparative perspective, drawing on the operational 
features of HTA systems from a wide range of countries. 
To this end, the paper provides a holistic approach to the 
process of value assessment and its implications for cover-
age, analyses how different applications of HTA can result 
in practice variations across settings and discusses how these 
variations impact HTA recommendations and, possibly, cov-
erage decisions.
2  Conceptual Framework
Earlier research [6, 14–16] has focused predominantly on 
studying HTA outcomes of the same technologies among 
different HTA bodies, while examining the clinical and/
or economic evidence submitted. Whilst the submitted 
evidence can differ due to national and/or regional eviden-
tiary requirements and preferences, there are other impor-
tant parameters that might shape or influence the way HTA 
How Can HTA Impact Funding?
2.1  Governance of Health Technology Assessment 
(HTA)
HTA bodies may either be independent review bodies oper-
ating at arm’s length of governmental structures or may 
be bodies integrated within governmental structures with 
decision-making and priority-setting responsibilities [20, 
21]. The key differences that distinguish arm’s length from 
integrated systems lie in (i) the degree of independence in 
the way HTA bodies operate within the healthcare system 
and (ii) the transparency of the process. Independent bodies 
are considered to be more transparent than integrated ones as 
the former tend to take a broader and more society-focused 
perspective into consideration [20, 21].
2.2  Type of Organisation Performing HTA
Different types of institutions can perform HTA or HTA 
activities [22]: (i) research institutions include academic 
bodies with broader research initiatives that could encompass 
some HTA activities; (ii) HTA-research institutions which 
have a special department dedicated to HTA activities; (iii) 
national insurance organisations; (iv) national/regional 
health organisations, which could be under the supervision 
of the Ministry of Health focusing on public health and 
pharmaceutical policy either at national or regional level 
but usually functioning at arm’s length of the government; 
(v) national/regional HTA authorities, which perform HTA 
as their main activity; (vi) governmental organisations that 
are integrated within the Ministry of Health, and (vii) drug 
regulators which authorise medicines and/or medical devices 
with a clear separate HTA function.
2.3  Role of HTA
HTA bodies can have an advisory, a regulatory or a coor-
dinating role in the decision-making process, depending 
on the intent and type of assessment required, the general 
mission and overall objectives of the review body [20, 23]. 
Advisory HTA bodies produce coverage recommendations 
for decision-makers [23], but the latter are not obliged to 
follow this advice or take it into consideration when negoti-
ating with manufacturers. By contrast, regulatory bodies are 
directly accountable to the Ministry of Health (MoH) and 
are responsible for the pricing and reimbursement of new 
technologies [23]. Hence, regulatory systems have an impact 
on pricing and coverage decisions compared to advisory 
systems. Coordination bodies usually conduct independent 
research on HTA and might be responsible for coordinat-
ing HTA activities at  national, regional and provider level 
[24]. HTA recommendations from coordination bodies are 
rarely considered or accounted for in coverage decisions. 
This is due to the nature of these bodies and the way they 
carry the assessment, which in most cases simply evaluates 
clinical and economic evidence without contextualising the 
healthcare system’s needs. However, healthcare systems can 
appoint a coordination body as an advisor and further pro-
duce recommendations that are used in decision-making.
2.4  Scope and Geographical Coverage of HTA
The structure of a healthcare system and the balance between 
local autonomy and centralised control influence how HTA 
systems are organised [21, 25]. Healthcare systems that 
make pricing and reimbursement decisions centrally, tend 
to conduct HTA centrally. Healthcare systems with decen-
tralised structures and resource allocation at a regional level 
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Fig. 1  Conceptual framework outlining type, scope and nature of 
HTA activities.  Source: The authors. 1 ‘Other technologies’ refers to 
public health interventions such as screening programmes, vaccina-
tion campaigns, evaluation of surgical and non-surgical interventional 
procedures, stem cell therapies, innovative cancer vaccines, cell and 
gene therapies, and other forms of personalised treatments 
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can justify HTA activities performed regionally. However, 
given the unique nature of healthcare systems, there are 
cases where HTA activities are taking place at both levels.
2.5  Remit of HTA
In principle, all types of medical technologies can undergo 
HTA, including pharmaceuticals, medical devices and 
‘other technologies’ [24, 26–28]. The precise remit of HTA 
showcases which technologies are subject to assessment for 
listing.
2.6  Model of HTA
There are three distinct HTA models which reflect the objec-
tives and priorities of healthcare systems [20]. First, the 
clinical and cost-effectiveness model uses both economic 
evidence and comparative clinical benefit to assess health 
technologies. Second, the comparative clinical benefit 
assessment model relies on ranking new interventions based 
on comparative benefit assessment. Under this model, the 
pricing decision is subject to negotiations between purchas-
ers and manufacturers. Third, the value-based assessment 
model is directly related to the aforementioned models and 
further takes into consideration explicitly additional dimen-
sions of value beyond effects and/or costs that are considered 
important, such as disease severity, burden of disease, treat-
ment innovativeness and equity considerations. It is possible 
that HTA bodies may adopt more than one HTA model based 
on certain criteria. For instance, in France, Haute Autorité de 
Santé (HAS) assesses technologies based on the comparative 
clinical benefit model. However, since 2013, submission of 
a cost-effectiveness analysis is mandatory for technologies 
with a moderate to major improvement in clinical benefit 
(ASMR I–III) [29].
2.7  Assessment Versus Appraisal
Assessment and appraisal are the two different facets of 
HTA [20, 24, 30]. Assessment refers to a process of collect-
ing, reviewing and synthesising clinical and economic evi-
dence to support funding decisions [8, 16]. Appraisal uses 
the same clinical and economic evidence but interprets it in 
the context of the healthcare system in question and takes 
into account factors that may be of relevance in that context 
[8, 16]. These contextual factors are known as social value 
judgements and can be both explicitly recognised, such as 
the end-of-life criteria in England and severity in France, 
or implicit, for example, the possible burden on patients’ 
activities of daily living or the impact on family and car-
ers [31]. The contextualisation of the evidence thus leads 
to recommendations that reflect the national/regional needs 
and values.
2.8  Stakeholder Involvement in HTA
Consultation of various stakeholders, including healthcare 
professionals, patients/patient organisations, citizens, health 
insurers, ethicists and the industry has become an essential 
part of HTA procedures, contributing to increased transpar-
ency, reduced appeals and inclusiveness. To ensure that HTA 
recommendations are considering preferences, values, judg-
ments, opinions and individual insights, stakeholder par-
ticipation can occur via two main routes: (i) stakeholders 
participate as members of an HTA committee, and (ii) stake-
holders are engaged through public calls (external engage-
ment). The way stakeholders are engaged and involved in 
the process varies across HTA systems and the type of stake-
holders involved can reflect the inclusiveness of the HTA 
process and its ability to incorporate values and preferences 
that matter to different segments of society.
2.9  HTA Recommendations and Funding Decisions
HTA recommendations can either be binding or non-binding 
to the final funding decision [22]. In the non-binding case, a 
negative recommendation is not necessarily associated with 
a negative coverage decision. In the binding case, purchas-
ers/commissioners of care are legally obliged to consider the 
HTA outcome when deciding on coverage.
3  Methods
3.1  Scope and Data Sources
The scope of our analysis captured the 27 European Union 
Member States (EU MS), the UK (England, Scotland, 
Wales and Northern Ireland), Australia and Canada and 
further includes the European network for Health Technol-
ogy Assessment (EUnetHTA) to account for joint assess-
ments conducted by more than one EU MS. We focused on 
Europe, the UK, Canada and Australia as they have, for a 
large majority, well established HTA systems that are used to 
inform national and regional funding decisions. The refine-
ment of processes that often accompany well established 
HTA systems allowed us to easily categorise our findings 
using the conceptual framework and to make comparisons 
across countries. Therefore, we included countries with 
explicit HTA systems defined as systems performing HTA 
routinely and whose existence is enshrined into legislation. 
We included multiple HTA bodies operating at both national 
and regional levels from the same country if they existed. We 
categorised the types of bodies/institutions performing HTA 
based on their nature and structure, where these institutions 
lie within the healthcare system and the way they are funded 
(e.g. research and HTA-research institutions are independent 
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of the government and do not necessarily receive their entire 
funding from the government). We excluded from our sam-
ple informal HTA processes, HTA-like activities (e.g. con-
sideration of pharmacoeconomic studies on an ad-hoc basis 
only), and mini-HTA activities (mainly assessing ambula-
tory care medicines or hospital technologies and, therefore, 
being small scale and not explicit) [17].
3.2  Secondary Data Collection
We used both primary and secondary sources to collect rel-
evant data. We collected evidence on the differences and 
similarities of HTA processes across the study countries 
through a search of the websites of all relevant competent 
authorities (including the MoH, national health insur-
ance organisations and the HTA bodies), EUnetHTA, the 
International Network of Agencies for Health Technology 
Assessment (INAHTA) and the ISPOR Global Health Care 
Systems Road Map. When we needed further clarification 
or additional information, we identified evidence through a 
literature search of Medline and Scopus, using the search 
terms ‘Health technology assessment (HTA)’ and the name 
of the country. We limited the literature search to English 
language. We conducted the secondary data collection from 
December 2016 to July 2018, and we updated the informa-
tion, when applicable, in March 2020. We created a list of 
all identified institutions undertaking HTA along with their 
websites.
3.3  Primary Data Collection Through Expert 
Consultation
We contacted 29 stakeholders via email in June 2019 to vali-
date and complement findings from secondary sources and 
provide further clarification on the nature of HTA activities 
and operational features in their respective countries. We 
purposively sampled these stakeholders to ensure the inclu-
sion of leading European health, HTA and pharmaceutical 
policy experts affiliated with universities and national com-
petent authorities, such as regulatory agencies, institutions 
responsible for pricing or reimbursement decisions and HTA 
agencies. In particular, we endeavoured to include experts 
from countries with less well-established HTA systems, 
since there was little available information from secondary 
sources in English. We asked the experts to (a) comment on 
the design of the conceptual framework; (b) confirm whether 
we had classified appropriately the key features of HTA 
systems according to  findings from secondary sources; (c) 
provide additional information about any formal or informal 
HTA activity taking place in their countries that we had not 
captured in our search (if applicable); and (d) provide details 
about how multiple organisations that undertake HTA activi-
ties within countries collaborate in relation to assessments 
and final decision-making (if the respondent was based in a 
country with more than one HTA agency).
4  Results
4.1  Final Sample of HTA Activities
We identified 63 HTA bodies/institutions undertaking HTA 
activities across 32 settings. We excluded Northern Ireland 
as HTA activities are very limited and rely on reviews of 
the English National Institute for Health and Care Excel-
lence (NICE) decisions [32]. We included EUnetHTA as a 
supranational organisation that has been created to coordi-
nate joint HTA activities at the EU level [27]. We further 
acknowledged the proposed regulation of the EU commis-
sion regarding HTA cooperation [33] but we did not con-
sider it in this study as it was still under deliberation and 
consultation at that time.
Out of the 29 contacted experts, 18 experts from 14 coun-
tries (Estonia, Ireland, Poland (n = 3), Portugal, Romania, 
Slovakia, Slovenia, Spain, Sweden (n = 2), Malta, Bulgaria, 
Austria (n = 2), Belgium and Czech Republic) responded 
to our call and participated in the consultation round. The 
results of the primary and secondary data collection are pre-
sented according to the attributes of the conceptual frame-
work. Table 1 summarises the key findings on the bodies 
or institutions undertaking HTA activities across the study 
countries (see Appendix Table 1 in the electronic supple-
mentary material [ESM] for complete results by country).
4.2  Governance of HTA
The majority (73%, n = 46) of the identified institutions are 
at arm’s length of government, including regulatory bod-
ies, which are by definition independent of government. 
Similarly, we categorised as independent organisations 
the national insurance organisations, which all perform in-
house HTA and use cost-effectiveness as one of the criteria 
for coverage decisions. This is because national insurance 
organisations are independent entities and do not function 
as governmental organisations, even though they are a part 
of national healthcare systems. Institutions or organisations 
that do not operate within the national or regional MoH are 
categorised as independent bodies. Integrated agencies to a 
governmental structure were predominately regional bodies 
or newly established HTA committees that are responsible 
for performing HTA within the MoH (e.g. Greece, Cyprus 
and Malta).
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4.3  Type of Organisation Performing HTA
Twenty-eight percent (n = 18) of the identified entities per-
forming HTA had formal HTA agency status, that is, HTA 
is their predominant activity. Twenty-two percent (n = 14) 
were national or regional healthcare organisations and 12% 
(n = 8) were governmental institutions (refer to Table 1 for 
all the different types of organisations performing HTA). 
There was variation across the sample as to which types of 
organisations perform HTA, showcasing that various types 
of organisations can undertake HTA activities predomi-
nantly depending on the structure of the healthcare system 
and the scope and objectives of HTA.
4.4  Role of HTA
According to our findings on the governance endpoint and 
the role of HTA bodies, we created a taxonomy (Fig. 2) to 
differentiate the included bodies based on their level of inte-
gration within the government, as well as their function as 
advisory, coordination or regulatory entities.
4.5  Scope and Geographical Coverage of HTA
In 13 countries (Austria, Belgium, Croatia, Estonia, Finland, 
Germany, Ireland, Lithuania, Slovakia, Slovenia, Sweden, 
England and Wales), we identified more than one institution 
with varying roles undertaking HTA activities at a national 
level. Stakeholders who participated in the expert consul-
tation from Austria, Belgium, Estonia, Slovakia, Slovenia, 
Sweden and Ireland provided additional information on the 
responsibilities of multiple national HTA bodies (see Appen-
dix 2 in the ESM for a detailed description on how multiple 
national HTA bodies are set up in a country’s system, how 
these bodies interact with each other and their impact on 
funding decisions). HTA bodies with a regional and pro-
vider-level scope were identified in eight countries (Austria, 
Canada, Germany, Italy, Spain, Denmark, Poland and Swe-
den). Due to limited access and data, we were able to include 
regional HTA bodies from Spain, Italy and Canada. In Spain 
and Italy, organisations performing HTA at a regional level 
are mainly integrated within the regional government. In 
Sweden, there are about 15 regional HTA bodies that assess 
the clinical and cost-effectiveness of procedures and medical 
devices; they have an advisory role to the county councils 
and help to inform reimbursement decisions at  state level. 
However, their recommendations are not binding [34]. Due 
to limited evidence, they were not included in our sample. 
In Austria, universities such as the University for Health 
Sciences Medical Informatics and Technology (UMIT), the 
IAMEV unit in the Medical University of Graz and the Dan-
ube University Krems (DUK) perform HTA activities inde-
pendently by assessing various health technologies. DUK 
and the IAMEV unit conduct clinical assessments whereas 
UMIT follows the clinical and cost-effectiveness model [34]. 
In Poland, hospital-based HTA is evolving and is performed 
by some university hospitals and institutes to support invest-
ment decisions in hospitals. However, their scope and impact 
on funding decisions are still unknown [34].
4.6  Remit of HTA
In the sample, there is wide variation in the technologies 
that undergo HTA. From our sample, we identified bod-
ies that assess a specific type of pharmaceuticals only. For 
instance, the Finnish Medicines Agency (FIMEA) in Finland 
performs HTA only for in-patient pharmaceuticals. SUKL 
in the Czech Republic performs HTA only for out-patient 
pharmaceuticals, while TLV in Sweden assesses mainly out-
patient pharmaceuticals, whereas in-patient pharmaceuticals 
are assessed at county level [34] (see Appendix 3 in the 
ESM for a detailed list of which technologies undergo HTA 
assessment by the identified HTA bodies).
4.7  Model of HTA
All national insurance organisations in Austria, Belgium, 
Croatia, Estonia, and Slovenia use the clinical and cost-
effectiveness model as an additional criterion during the 
decision-making process on what technologies to include 
in their reimbursement lists. In Sweden, value-based assess-
ments by TLV always take into consideration explicitly the 
human dignity and solidarity principles to derive funding 
decisions [34]. In Slovakia, since the new legislation was 
implemented in 2011, decisions on resource allocation are 
based on criteria beyond the clinical effectiveness, safety 
and the economic benefit of the technologies, notably, dis-
ease severity, impact on society and risk of abuse [34]. In 
France, the award of total therapeutic benefit (SMR) and 
improvement in therapeutic benefit (ASMR) rests on cri-
teria beyond efficacy; for example, ASMR I is awarded to 
significant innovations in terms of efficacy improvement in 
a severe disease setting, in other words, severity is taken 
explicitly into account; similar criteria inform the SMR rat-
ing. Therefore, additional dimensions of value are taken into 
account during the assessment and appraisal process.
4.8  Assessment Versus Appraisal
Fifty-six percent (n = 35) of HTA bodies perform apprais-
als and are not solely collecting and synthesising evidence 
on the clinical and/or economic effectiveness of technolo-
gies. HTA bodies conducting appraisals are mainly national 
institutions. Approximately 44% (n = 28) of the HTA bodies 
limit their evaluations in the assessment phase. Regional 
HTA bodies in Spain, Italy and Canada, research institutions 
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Table 1  Summary of HTA systems across EU Member States, the United Kingdom, Canada and Australia
Variable Summary of evidence Country examples
Governance of HTA Arm’s length: 46 Austria, Croatia, Finland, the Netherlands, 
Canada, England, France, Germany, Australia, 
Poland
Integrated: 16 Cyprus, Greece, Malta, Slovakia, Slovenia, Italy, 
Spain (regional), Canada (regional)
N/Aa: 1 EU level
Type of organisation performing HTA Research institution: 6 Austria, Belgium, Denmark, Estonia, Slovakia, 
England
HTA research institution: 6 Austria, Finland, Ireland, Lithuania, Spain 
(national and regional)
Drug regulator: 6 Czech Republic, Finland, Hungary, Italy, Portu-
gal, Romania
Governmental institution: 8 Cyprus, Greece, Lithuania, Luxembourg, Malta, 
Slovakia, Slovenia, Spain
HTA authority: 18 France, Germany, Poland, Scotland, England, 
Wales, EU level, Canada, Australia
National/regional healthcare organisation: 14 Bulgaria, Croatia, Finland, Germany, Italy, Latvia, 
Lithuania, the Netherlands, Spain, Sweden
National insurance organisation: 5 Austria, Belgium, Croatia, Estonia, Slovenia
Role of HTA Advisory: 33 Luxembourg, the Netherlands, Portugal, England, 
Canada, Australia
Coordination: 2 Finland, UK
Regulatory: 17 Bulgaria, Croatia, Cyprus, Czech Republic, Italy, 
Estonia, Germany, Sweden
Advisory and coordination: 10 Austria, Belgium, Denmark, Ireland, Spain 
(national and regional), Canada
N/Aa: 1 EU level
HTA scope National: 48 Australia, Germany, France, Sweden, Slovakia, 
Austria, Lithuania, Malta, Luxembourg, the 
Netherlands
Regional: 14 Spain (AQuAS–Catalonia, OSTEBA–Basque 
County, AETSA–Andalusia, SECS–Canary 
Islands, UETS–Madrid, Avalia-t–Galicia, 
IACS–Aragon), Italy (AGENAS, CRU–Veneto, 
ER Salute–Emilia Romagna), Canada (INESSS–
Quebec, HQO–Ontario, CED–Ontario, British 
Columbia)
N/Aa: 1 EU level
Remit of  HTAb Pharmaceuticals: 48 Austria, Belgium, Bulgaria, Croatia, Cyprus, 
Finland, France, Germany, Greece, Malta, Scot-
land, Australia, Canada
Medical devices: 41 Denmark, Hungary, Ireland, Latvia, Lithuania, 
Portugal, Spain, Sweden
Other technologies: 33 Canada, EU level, England, Wales, Sweden, the 
Netherlands, Lithuania, Belgium, Croatia
All: 20 Belgium, Estonia, France, Finland, the Nether-
lands, Poland, England, EU level
Model of HTA Comparative clinical benefit assessment: 7 Austria (GÖG and LBI), Germany (GBA and 
IQWiG),  Greecec, Slovenia (Health Council), 
EU level
Clinical and cost-effectiveness: 46 Belgium, Croatia (both agencies) Cyprus, Spain 
(national and regional), Malta, Lithuania, Ire-
land, Finland, Hungary, Denmark, Wales
Clinical and cost-effectiveness/MCDA: 2 Bulgaria, Canada
Value-based assessment: 8 France, Slovakia (both HTA bodies), Slovenia 
(ZZZS), Sweden, England, Scotland, Australia
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and integrated committees within the MoH responsible for 
HTA in Malta, Greece, Bulgaria and Cyprus are all perform-
ing assessments rather than appraisals.
4.9  Stakeholder Involvement in the HTA Process
Involvement of various stakeholders as members of HTA 
committees was present across almost all the HTA bodies 
except bodies with a coordination role in Denmark, Finland 
and England, where assessments are performed by external 
institutions. The type of stakeholders involved in decision-
making varied considerably across countries from repre-
sentatives of healthcare insurance funds and public health 
organisations, healthcare experts, ethicists, health econo-
mists, healthcare professionals as well as patient and citizen 
advocates. External expert consultation was not present in 15 
HTA bodies, which, in their majority, were regulatory bod-
ies. External consultation was heavily dependent on patients 
who were able to submit their opinion on the topic selection, 
the evaluation process or the final recommendations.
4.10  HTA Recommendations and Funding Decisions
Positive  HTA recommendations are not always trans-
lated into funding decisions regardless of how well HTA 
systems are developed, their role and what their position 
is with in the healthcare system. In 81% (n = 51) of our 
sample, HTA outcomes are non-binding and their impact 
during reimbursement negotiations is unclear. Nevertheless, 
HTA outcomes, even if non-binding, weigh heavily on final 
reimbursement decisions in some countries such as France, 
England, Scotland, Australia, Poland and Romania [34]. In 
Table 1  (continued)
Variable Summary of evidence Country examples
Assessment versus appraisal Assessment only: 28 Austria, Belgium, Croatia, Cyprus, Estonia, Den-
mark, Greece, Ireland, Italy (regional), Spain 
(regional), EU level, Canada (regional)
Assessment and appraisal: 35 Austria, Belgium, France, Finland, Croatia, 
Canada, Australia, Romania, Luxembourg, 
Portugal, Poland, Slovenia, Sweden, Spain, 
England, Scotland, Wales
Stakeholder involvement in HTA Stakeholder participation as members of 
HTA committee: 59
Croatia, Cyprus, Finland, Greece, the Nether-
lands, Portugal, Poland, Spain, Sweden, Canada, 
Australia
Stakeholders through public calls: 48 Austria, Belgium, Bulgaria, Croatia, Czech 
Republic, Denmark, Estonia, Finland, France, 
Ireland, Latvia, Lithuania, Malta, Portugal, 
Slovakia, Slovenia, Spain, UK, EU level
HTA recommendations and funding decisions Binding: 12 Bulgaria, Cyprus, Finland, Germany, Italy, Lithu-
ania, Portugal, Sweden
Non-binding: 51 Austria, Belgium, Croatia, Denmark, Estonia, 
Finland, France, Germany (both HTA bod-
ies), Greece, Hungary, Ireland, Italy (regional), 
Poland, the Netherlands, Spain, Wales, Canada, 
EU level
Publicly available reports Yes: 48 Australia, Canada, England, Scotland, Wales, 
Sweden, Spain, the Netherlands, Germany, 
Belgium
No: 15 Croatia, Estonia, Greece, Hungary, Luxembourg, 
Slovakia, Slovenia
Source: The authors, based on primary and secondary data collection
EU European Union, EUnetHTA European network for Health Technology Assessment, HTA health technology assessment, MCDA multiple-
criteria decision analysis, N/A not applicable
a EUnetHTA has been categorised as a supranational organisation that has been created and now coordinates the HTA Core Model, which is a 
methodological framework for collaborative production and sharing of HTA information. Therefore, EUnetHTA does not fall into the classifica-
tion in which we have placed national HTA bodies
b Under the remit of HTA, different organisations in each country may perform HTA for different technologies. Examples of agencies that per-
form HTA for pharmaceuticals only are SUKL in the Czech Republic and DPA in Malta. Examples of agencies that perform HTA for medical 
devices only are AGENAS in Italy and UETS in Spain. Examples of agencies that perform HTA for other technologies are SBU in Sweden and 
the Institute of Hygiene in Lithuania
c In Greece, cost-effectiveness is envisaged in legislation, but is currently not mandatory and no cost-effectiveness threshold has been published
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Poland, the HTA authority (AOTMiT) plays a key role in 
the reimbursement process. Any health technology that is 
subject to coverage by the public healthcare system has to 
be assessed by AOTMiT. Both the president of the agency 
and the Transparency Council (TC), serving as an advisory 
body to the president, provide a formal position [34]. Non-
binding recommendations are submitted to the MoH, where 
negotiations are taking place between the MoH Economic 
Commission and the manufacturer. The MoH makes the 
final decision, taking into consideration the opinions of both 
the TC and the president as this is one of the reimburse-
ment criteria established by law [34]. In Romania, legisla-
tion stipulates that the HTA authority (ANMDM) makes a 
recommendation to the MoH based on a scorecard and a 
budget impact analysis. Scorecard points are given, taking 
into account HTA recommendations, in England, Scotland, 
France and Germany. Additional points are further attrib-
uted when the product under evaluation has been granted 
reimbursement status in EU countries. According to primary 
evidence, the MoH will always include in the reimbursement 
list products with a positive recommendation by ANMDM 
[34]. Moreover, if ANMDM makes a conditional reimburse-
ment recommendation, then the manufacturer must submit 
a request to the National Health Insurance House to attend 
price-volume negotiations. The request is analysed by a 
negotiation commission that decides if contract negotiations 
will be initiated [34]. In England and Scotland, NICE and 
SMC have an advisory role and the local NHS must fund 
all positive HTA recommendations. Technologies receiving 
a negative recommendation may be subject to negotiations 
in order to improve their cost-effectiveness and if there is 
agreement then the NHS will fund the technology; alterna-
tively, if clinical benefit is highly uncertain or is considered 
inadequate, alternative mechanisms or pathways exist [35, 
36]. In Australia, the government or the cabinet should con-
sider all HTA recommendations by PBAC if the medicine 
is expected to cost more than AU$20 million per year [37].
5  Discussion
The results in this study point to a number of key features 
of HTA processes and their relationship to coverage deci-
sions. First, HTA is not a single mechanism but consists of 
several salient features that can differ substantially across 
countries and further determine the way it is implemented to 
inform coverage decisions. HTA operates mainly at national 
level except in countries with decentralised systems (e.g. 
Italy, Spain, UK, Sweden) or autonomous regions/provinces 
(e.g. Canada). As such, HTA infrastructure and activities 
HTA Systems
Arms’ Length body HTA function incorporated/integrated
Advisory Regulatory
Coordination
Advisory RegulatoryAAZ (Croatia) 
HAS (France)
IQWiG (Germany)
OGYÉI (Hungary)*
FIMEA (Finland)*
NCPE (Ireland)
HIQA (Ireland)
HI (Lithuania)
ZiN (the Netherlands)
AOTMiT (Poland)
SiNATS (Portugal)*
AGENAS (Italy)
CRU (Venetto, Italy)
NICE (England, UK)
SMC (Scotland, UK)
HTW (Wales, UK)
AWMSG (Wales, UK)
UT (Estonia)
IACS (Aragon, Spain)
PBAC (Australia)
CADTH (Canada)
INESSS (Quebe, Canada)
HQO (Ontario, Canada)
GÖG (Austria)
LBI-HTA (Austria)
KCE (Belgium)
DEFACTUM 
(Denmark)
FinCCHTA 
(Finland)
ISCIII (Spain-
National)
SBU (Sweden)
NIHR (England, 
UK)
UNIBA FoF 
(Slovakia)
HVB (Austria)
INAMI (Belgium)
HZZO (Croatia)
EHIF (Estonia)
G-BA (Germany)
AIFA (Italy)*
ANMDM 
(Romania)*
ZZZS (Slovenia)
TLV (Sweden) 
SUKL (Czech 
Republic)*
HILA (Finland)
NCPR (Bulgaria)*
VASPVT 
(Lithuania)
NVD (Latvia)
HTA committee of 
MoH (Greece)
MoH (Lithuania)
Pricing committee of 
MoH (Cyprus)
CEM (Luxembourg)
MoH (Slovakia)
AQuAS (Catalonia, Spain)
SECS (Canary Islands, 
Spain)
ER Salute (Emilia 
Romagna, Italy)
Avalia-T (Galicia,Spain)
Health Council  of 
MoH(Slovenia)
OSTEBA (Basque 
country, Spain)
AETSA (Andalusia, 
Spain)
UETS (Madrid, Spain)
DPA (Malta) 
CED (Ontario, Canada)
Health Technology 
Assessment Committee 
(British Columbia, 
Canada)
Fig. 2  Taxonomy of HTA bodies.  Source: The authors, based on primary and secondary data collection. *Regulatory body for approval of 
medicines and/or medical devices with a clear separate HTA function
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reflect the structure of the healthcare systems in which they 
operate. The scope of HTA systems can directly mirror the 
administrative division of a country (highly regional systems 
vs centralised ones). In countries where HTA activities are 
performed both at national and regional level, assessments 
of clinical benefit for the same technology could amount to 
duplication of effort. Similarly, when considering compa-
rable HTA structures across Europe, assessment of clinical 
evidence performed by HTA agencies duplicates effort as 
manufacturers tend to submit very similar, if not the same, 
evidence. Therefore, EU HTA cooperation may be able to 
streamline HTA activities and homogenise methodologies 
and procedures in assessing health technologies within the 
European Union [22].
Second, institutions performing HTA at national level 
are mostly independent from the competent authorities they 
serve (e.g. Ministries of Health, health insurance organisa-
tions, pricing committees), even though their activities may 
be sometimes supervised by these authorities. Consider-
ing that HTA activities can, in general, be grouped into (a) 
assessment, (b) appraisal, (c) coverage recommendations, 
and (d) funding negotiations, the remit of independent bod-
ies covers (a), (b) and (c), while integrated bodies cover (a), 
(b) and (d). Given that HTA recommendations by integrated 
bodies can result in negotiations, they can play a key role 
in funding decisions. However, this depends on the role of 
the HTA and whether  recommendations are binding or not. 
Overall, HTA bodies operating at arm’s length are present 
in more developed HTA systems and tend to be transpar-
ent and independent, avoid conflicts of interest and offer 
dispassionate advice on the costs and/or effects of assessed 
technologies adapted for contextual considerations. By con-
trast, newly founded and less well-developed HTA systems 
such as those found in Greece, Cyprus and Malta tend to 
be integrated within existing competent authorities. They 
may lack transparency as assessments are internalised, and 
recommendations are not reported in publicly available 
documents, rendering decision-making and negotiation pro-
cesses unclear and non-transparent. Nevertheless, it could 
be argued that integrated HTA functions can be very useful 
as a starting point in the implementation of HTA activities, 
particularly in circumstances where there is a lack of capac-
ity for the development of an independent HTA body. Unsur-
prisingly, most independent bodies make their HTA reports 
and outcomes publicly available (see Appendix in the ESM), 
whereas integrated bodies tend to keep their reports confi-
dential. Overall, more transparency improves the extent to 
which a decision can be controlled by the organisation that 
has commissioned it in the first place [38].
Third, irrespective of operating at arm’s length or being 
integrated with competent authorities, the majority of HTA 
bodies have an advisory role where HTA outcomes act only 
as recommendations and can be used as supplementary tools 
or additional criteria during negotiations. HTA bodies with 
a coordination role may operate in an advisory capacity to 
competent authorities when asked to assess technologies, 
however, the extent of their contribution to the final coverage 
decision is unclear and the consideration of their recommen-
dation is mostly made in a non-systematic manner. Coor-
dination bodies are few and, in our opinion, entities with 
this role are urgently needed to assist with the coordination 
and interoperability of HTA activities as well as to generate 
evidence on how new technologies impact society, including 
cost–benefit analyses. Coordination bodies can also assist 
in the transformation of HTA recommendations into clini-
cal guidelines contributing to optimal resource allocation 
by positioning new technologies along treatment pathways, 
monitoring their use and assessing the impact they have.
Fourth, the type of HTA evaluation plays an essential 
role in the way HTA outcomes are translated into funding 
decisions. During the assessment phase, comparative clini-
cal and/or economic evidence is reviewed, whereas during 
the appraisal phase, the evidence is assessed and interpreted 
based on its scientific rigour, the achievement of the end-
points of interest, the design of the included studies, the 
economic effectiveness, the budget and/or economic model 
submitted and a other contextual considerations that may 
be relevant to the setting in question. Value dimensions are 
examined to investigate the extent to which a new technol-
ogy is relevant for the healthcare system of interest [39]. 
Under appraisal these dimensions are always taken into con-
sideration regardless of their nature and the disease context. 
Therefore, when appraisals are performed, recommendations 
are context-specific as they take into consideration how a 
technology can be adopted at national or regional level and 
what budget impact it will have. Appraisals can inform pur-
chaser–manufacturer negotiations by providing steer, among 
others, on whether any risk mitigation strategies should be 
implemented.
Fifth, the vast majority of HTA bodies or HTA-perform-
ing institutions have some form of stakeholder involvement 
or engagement. Whether stakeholders were involved in the 
HTA process itself or whether they were part of the HTA 
committee varied, with more developed and well established 
systems giving patients, carers, citizens and health experts 
the possibility to act as external stakeholders through public 
calls. However, engagement of external stakeholders does 
not always serve the same purpose and ranges across sys-
tems from opinions and insights on topic selection and scop-
ing to consultations during HTA assessment or appeals on 
the final recommendations. In many systems where patient 
representatives or patient organisations are not involved in 
HTA, members who are ethicists are bringing the societal 
perspective into decision-making. However, even though, 
in theory, stakeholder participation or engagement can 
result in better uptake of HTA recommendations, there is 
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no evidence establishing a direct link. Undoubtedly, partici-
pation of healthcare experts and professionals, experts on 
ethics, patients, their families and carers in either the HTA 
process itself or decision-making can ensure transparency, 
inclusiveness and the reflection of different perspectives in 
the final recommendations.
Sixth, to assess whether HTA recommendations are trans-
lated into funding decisions, we looked at whether HTA out-
comes across our sample countries are legally binding. This 
means that decision-makers are legally bound to respect and 
follow the final HTA recommendations when making cover-
age decisions. Based on our findings, the majority of HTA 
systems issue non-binding recommendations; however, the 
importance and the weight these recommendations might 
have on the decision-making process vary across countries. 
In less-developed HTA systems, such as that of Greece, the 
role and the impact of HTA recommendations, which are 
non-binding, is still unknown due to lack of transparency in 
the decision-making process. Nevertheless, from our sample 
we identified countries such as Poland, France, England, 
Scotland, Australia and Romania where recommendations 
are non-binding but their role during pricing and reimburse-
ment processes at national level is considered crucial.
In order to be able to capture all types of recommenda-
tions, we created three alternative scenarios on how HTA 
outcomes feed into final funding decisions and what their 
contribution to the final coverage decision of technologies 
is. Fig. 3 shows three categories of recommendations: (i) 
binding; (ii) non-binding but as impactful as binding and 
(iii) non-binding. We created the second category to be able 
to include the HTA systems of England, Scotland, Australia, 
France, Poland and Romania, which have an advisory role 
according to legal statutes, however (positive) recommen-
dations are considered binding for coverage purposes. For 
instance, the NHS in England is legally obliged to fund 
technologies recommended by NICE and ensure they are 
available within 3 months from the date of the NICE recom-
mendation being published [34].
HTA recommendations that do not fall into the first two 
categories might jeopardise transparency by creating uncer-
tainty on how evidence-based information is used meaning-
fully during negotiations or is translated into either price 
discounts or any other type of Managed Entry Agreements. 
Importantly, however, non-binding HTAs might inform deci-
sion processes further upstream. For instance, in the Greek 
context, the HTA committee’s recommendations inform the 
negotiation committee, which has decision-making power 
over what is reimbursed. In Poland, HTA recommenda-
tions play an important role and are extensively used by the 
MoH, which decides on reimbursement based on negotia-
tions between the Economic Commission of the MoH and 
the manufacturer [34].
Seventh, while HTA systems across the study countries 
seem to have well developed processes for the assessment 
of pharmaceuticals, these do not appear to be in place for 
medical devices and other technologies, including public 
health interventions; there is significant need for refine-
ment in the assessment of both medical devices and other 
technologies [24]. Among other reasons, this is due to the 
highly fragmented market structure of medical devices, the 
lack of clear guidance on evidence requirements and the 
inconsistency in the methods employed in their assessment 
[24]. Overall, the range of relevant technologies undergoing 
HTA is determined by budget holders wishing to optimise 
the available resources. The identification of more than 
one HTA agency at national level often coincided with the 
identified HTA bodies having different remits and assess-
ing different health technologies. For instance, in Wales the 
All Wales Medicines Strategy Group (AWMSG) assesses 
pharmaceuticals only, while Health Technology Wales 
(HTW) assesses medical devices and other technologies. 
This was further validated by experts who participated in 
the consultation round: according to primary evidence, the 
majority of countries reporting more than one body/institu-
tion performing HTA at national level, except Belgium and 
Estonia, have different national bodies for the assessment 
of different technologies.
Finally, there are different avenues for how HTA recom-
mendations can be used depending on the way HTA sys-
tems operate, their role, and the technologies undergoing 
assessment, such as (i) reimbursement and coverage, (ii) 
price setting, (iii) strategic purchasing and procurement, 
especially for medical devices, and (iv) to inform clinical 
guidance. For instance, HTA bodies with a coordination 
role can rarely impact coverage decisions but their recom-
mendations can be used for the update of clinical guide-
lines. HTA systems across our sample could be further 
divided into several categories in terms of the way HTA 
recommendations are implemented in decision-making. 
We observed systems where HTA outputs provide a fun-
damental basis for pricing and reimbursement; for exam-
ple, in France, HTA recommendations are used both for 
reimbursement decisions by the national insurance fund 
and for pricing decisions by the TC. Other systems, such 
as that of England, operate in a manner whereby the HTA 
body makes a recommendation that eventually might trig-
ger negotiations if the cost-effectiveness threshold is higher 
than the acceptable range or when there is considerable 
clinical uncertainty around the technology under evalua-
tion. In this case, negotiations take place outside the remit 
of the HTA body between the purchaser/commissioner of 
care and the manufacturer. Lastly, there are HTA systems 
such as that of Australia or HTA by health insurance funds 
that internalise the decision-making process. Under these 
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systems, negotiations, risk-sharing agreements or strategic 
purchasing and procuring take place within the HTA body 
based on the HTA outcome of the body itself. Despite how 
HTA recommendations are implemented, it is important to 
highlight that the ultimate ‘client’ of the HTA bodies is the 
healthcare system they operate in.
Our study is not without limitations. (a) Due to una-
vailability of data and limited access, we were not able to 
identify all regional HTA bodies across study countries. (b) 
Reliance on secondary sources has meant that it may not 
have been possible to capture HTA processes and imple-
mentation in detail. (c) Some HTA bodies may consider 
additional dimensions of value beyond clinical benefit and 
cost-effectiveness. Nevertheless, it has not always been pos-
sible to determine whether these features have an explicit 
impact on HTA recommendations through literature or 
expert opinion. (d) Even though we tracked the HTA sys-
tems across countries, the actual implementation and uptake 
of HTA activities during funding decisions were not fully 
captured. In order to address the latter two limitations, we 
performed the round of expert consultation to improve our 
understanding of the role and extent of HTA uptake at the 
national/regional level.
6  Conclusion
Based on a conceptual framework and taxonomy, we out-
lined the main operational pillars of HTA, showcased how 
HTA systems are set up within countries, how well devel-
oped HTA processes are as well as identified the different 
facets of HTA systems across the EU, the UK, Canada and 
Australia. Countries may follow similar pathways in the way 
HTA systems are set up, their role, remit and the way HTA 
processes are implemented, however, there are variations in 
the way HTA recommendations are translated into funding 
decisions. These relate to how well HTA processes are devel-
oped and integrated into  decision-making and the extent to 
which purchasers/commissioners of care consider evidence-
based information when deciding funding of technologies. 
While HTA processes are well established for pharmaceuti-
cals across the study countries, there seems to be a need for 
the development of established HTA processes for medical 
devices and other technologies. HTA is a dynamic and trans-
formative process which constantly adapts to new types of 
evidence, innovative technologies, and redefined objectives 
of healthcare systems. Even though HTA is now present 
across many settings, there is still an unmet need to make 
reimbursement and negotiation processes more transparent 
Explore other funding 
mechanisms
Non-binding but equally 
impactful as binding  
Negotiations with manufacturer- Managed 
entry agreements 
Review of recommendation by 
decision-maker/payer
Preparation for listing-quality 
and availability checks Final funding 
decision
Examples: England, France, Scotland, 
Australia, Poland, Romania
Positive HTA 
recommendation
Binding Final funding decision
Examples: Sweden, Bulgaria, Germany, 
Italy, Latvia
Positive HTA 
recommendation
Non-binding 
Explore other funding mechanisms
Negotiations with manufacturer 
Review of recommendations by 
other decision committees or 
decision-makers or regional 
authorities
Examples: Austria, Belgium, Denmark, 
Greece, Canada (Federal)
Consideration of other reimbursement policies or 
criteria
1 
2 
3 
Positive HTA 
recommendation
Final funding 
decision
Fig. 3  Positive HTA recommendations and links to final funding decisions.  Source: The authors. The dotted lines show the use of alternative 
pathways
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to better understand how purchasers/commissioners of care 
use HTA recommendations during negotiations with manu-
facturers, and to further investigate the extent to which HTA 
recommendations can influence coverage decisions.
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